

Out think. Out perform.

## A defensive shelter amid market uncertainties

The recent coronavirus outbreak is likely to have minimal impact to the Malaysia healthcare sector in the near term. Nevertheless, long term, we believe the rising healthcare awareness arising from the outbreak should be positive for the sector. We maintain our Overweight rating on the Healthcare sector and recommend investors to position defensively in the sector. Our top pick is Apex Healthcare. On a positive note, a possible retraction of the proposed medicine price controls, potentially due to the already competitive pricing in Malaysia and the fear of losing access to the latest and most innovative single-source medicines, could be a positive catalyst to the private hospital operators.

### Coronavirus outbreak likely to have minimal impact to the sector

We think that the coronavirus outbreak is likely to have only a muted impact on the private hospital operators as the private hospitals are required to report and refer such cases to public hospitals and the national infection centre based on MoH guidelines. While we note that the pharmaceutical players could potentially benefit from a surge in demand for products related to the prevention of seasonal viral diseases with similar symptoms, the impact to their respective bottom lines is likely to be minimal.

### Relatively resilient amid market uncertainties

Although not entirely recession-proof, healthcare spending is relatively inelastic and less prone to market uncertainties. Healthcare stocks under our coverage have long-term adjusted betas of <1, displaying the low sensitivity of the sector to global growth.

### Proposed medicine price controls likely to be called off

We gather that the proposed medicine price controls may not materialise in the near term, possibly because medicine prices in Malaysia are already relatively competitive and due to the risk of losing access to the latest and most innovative medicines. Alternatively, declaration of prices may be encouraged to improve transparency and encourage competition. We think that the possible calling off of the proposed medicine price controls could help to mitigate the current overhang on the private hospital operators.

### Maintain Overweight, with Apex Healthcare as our top pick

We maintain our Overweight view on the sector with Apex Healthcare as our preferred pick. We continue to like the sector for its defensiveness and long-term growth prospects. Going into 2020, we recommend positioning in the pharmaceutical space as a potential earnings recovery play and beneficiary of the government's initiatives to liberalise the drug distribution in the country. Key downside risks include sharp declines in patient volumes, higher-than-expected start-up losses for new hospitals, execution risk, currency risk, product recall risk and regulatory risk.

### Peer Comparison

Company Name	Rating	Share Pr (RM)	TP (RM)	Mkt Cap (RMbn)	Year end	Core PE (x)		Core EPS growth (%)		EV/EBITDA (x)		P/BV (x)	ROE (%)	Div Yield (%)	
						CY19E	CY20E	CY19E	CY20E	CY19E	CY20E	CY19E	CY19E	CY19E	CY20E
APEX HEALTHCARE	BUY	2.35	2.67	1,109.8	Dec	19.9	15.0	(7.4)	32.2	13.2	10.0	2.6	13.2	1.6	2.1
IHH HEALTHCARE	BUY	5.70	6.20	50,011.7	Dec	51.0	45.5	4.0	12.0	19.4	17.6	2.2	4.3	0.5	0.5
KPJ HEALTHCARE	HOLD	0.96	0.97	4,106.9	Dec	22.5	21.5	4.7	4.3	11.6	11.0	2.0	8.8	2.0	2.0
YSP SOUTHEAST ASIA	BUY	2.26	3.00	315.5	Dec	12.1	10.6	(20.2)	14.6	5.9	5.2	1.0	7.9	3.3	3.8
<b>Average</b>				<b>55,543.9</b>		<b>44.6</b>	<b>39.9</b>	<b>2.9</b>	<b>11.9</b>	<b>17.9</b>	<b>16.3</b>	<b>1.9</b>	<b>4.9</b>	<b>1.8</b>	<b>2.1</b>

Source: Bloomberg, Affin Hwang forecasts Note: Pricing as of 11 February 2020

### Sector Update

## Healthcare

### OVERWEIGHT (Maintain)

#### Absolute Performance (%)

	1M	3M	12M
IHH	1.8	4.8	1.8
KPJ	1.1	3.8	-8.6
APEX	4.0	2.2	14.2
YSP	-2.2	-3.0	-17.3

#### Relative Performance (%)



Source: Affin Hwang, Bloomberg

Chua Yi Jing  
 (603) 2146 7546  
 yijing.chua@affinhwang.com

## Screening for impact from coronavirus outbreak

### **No significant impact to the private hospital operators...**

As at latest count, the coronavirus has spread to 28 countries with over 43,000 confirmed cases and more than 1,000 deaths. Malaysia has recorded 18 confirmed coronavirus infections, while its neighbour, Singapore, has reported 47 confirmed cases. We do not expect the outbreak to have any significant impact to the private hospital operators in the near term. We understand that, for any pandemic case, private hospitals are required to report and refer these cases to public hospitals and the national infection centre, according to the Ministry of Health (MoH) guidelines.

### **... as well as patient volume growth**

So far the private hospital operators have not seen any significant surge in patient volume. While some may expect a surge in patient volume as patients with virus-like symptoms would likely seek doctor consultancy or treatment during this critical period, there are also patients who may defer non-urgent and non-essential cases to avoid the possibility of getting cross-infected in hospitals, which may in turn lead to lower patient volume. There is no meaningful historical data for comparison as KPJ's strong patient volume growth during SARS in 2002-2003 was mainly driven by acquisitions of existing hospitals (number of hospitals increased from 2 to 12; inpatient volume grew 223%), while IHH was not listed back then. All in, at this juncture, we believe the impact of the outbreak to private hospital operators is likely to be minimal.

### **Potential spill-over benefit to pharmaceutical players...**

Given that the speed of contagion is nearly double that of its predecessor SARS, we noticed there is an obvious trend of rising health awareness which has led to higher demand for products related to prevention of seasonal viral diseases with similar symptoms such as flu, cough and fever. A lot of people are rushing to pharmacies, convenience stores and Chinese medicine shops to stock up on face masks, hand sanitisers, consumer health products and herbal products, especially those that could help boost the immune system such as Vitamin C and liquorice. We think that this could potentially benefit the pharmaceutical players that are involved in the production, wholesale, distribution and/or retail of the abovementioned products. Based on our channel checks, most of the pharmaceutical players have seen a strong surge in demand for these products.

### **... but could be minimal to bottom line**

That said, we note that it is difficult to quantify these potential positives given the lack of available data, i.e., a breakdown of the revenue contributions from these products to the groups. Based on our estimates, the contributions from these products to the pharmaceutical players are not very significant, hence the impact to bottom line from the surge in demand for consumer health products is likely to be minimal relative to the group as a whole. Nevertheless, long term, we believe the rising health consciousness should be positive to the sector as people are increasingly aware of the need to stay healthy and keep their immune system strong.

Outthink. Outperform.

Fig 1: Local listed pharmaceutical players

Local listed pharmaceutical players	Details
Apex Healthcare (BUY, TP: RM2.67)	Involved in the distribution and wholesale of face masks such as surgical masks and N95 masks. The group also operates a retail pharmacy store, Apex Pharmacy, in Melaka.
Y.S.P. Southeast Asia (BUY, TP: RM3.00)	Involved in the manufacturing of consumer health products and TCM which contributed 1% and 9% to the group's revenue respectively. Of the consumer health products, YSP produces Vitamin C under its own brand, <b>Shine</b> .
Duopharma Biotech (Not rated)	Involved in the manufacturing of consumer health products which include Vitamin C. Duopharma is a market leader for Vitamin C products via <b>Flavettes</b> (for adults) and <b>Champs</b> (for children).
Pharmaniaga (Not rated)	Involved in the manufacturing of consumer health products which include Vitamin C under its own brand, <b>Citrex</b> . The group also operates 6 retail pharmacy outlets named RoyalePharma Pharmacy.
Bioalpha Holdings (Not rated)	Involved in the manufacturing of consumer health products, including those that help to improve respiratory health, strengthen the immune system and provide relief for coughs and colds such as <b>Apotec B-Ligno</b> and <b>Apotec Probiotics</b> . The group also operates 21 Constant pharmacies in Malaysia, which sell face masks, hand sanitisers and Vitamin C.
Caring Pharmacy (Not rated)	The largest local listed retail pharmacy operator with around 125 outlets across Malaysia. The group sells different brands of face masks, hand sanitisers as well as consumer health products at its pharmacy outlets.
Kotra Industries (Not rated)	Involved in manufacturing of Vitamin C under its own brand, <b>Appeton</b> .

Source: Companies, Affin Hwang

Fig 2: Vitamin C brands manufactured by local listed pharmaceutical players




Source: Companies, Affin Hwang

Outthink. Outperform.

**Relatively resilient amid market uncertainties**

Although not entirely recession-proof as a slowdown in the economy may also affect patient volume, with patients deferring non-urgent and non-essential cases, healthcare spending is relatively inelastic and less prone to market uncertainties. Hence we believe the sector provides a defensive shelter for investors in which to diversify. Healthcare stocks under our coverage have an average long-term adjusted beta of only 0.65 (10-year) and 0.77 (since listing) based on the latest data on Bloomberg, displaying the low sensitivity of the sector to global growth. Overall, we believe that the healthcare sector will continue to enjoy relatively resilient growth, underpinned by: i) ageing population, ii) rising affluence, iii) rising healthcare awareness, iv) growing healthcare expenditure, v) rising medical insurance, and vi) increasing life expectancy.

**Fig 3: Adjusted beta of healthcare stocks under our coverage (all <1)**



Source: Bloomberg, Affin Hwang

**Fig 4: IHH has an adjusted beta of only 0.77 since listing**



Source: Bloomberg

**Fig 5: KPJ has an adjusted beta of only 0.83 since listing**



Source: Bloomberg

Outthink. Outperform.

Fig 6: APEX has an adjusted beta of only 0.76 since listing



Source: Bloomberg

Fig 7: YSP has an adjusted beta of only 0.70 since listing



Source: Bloomberg

## Potential positive catalyst to private hospitals

### Proposed medicine price controls could potentially be called off

We gather that the proposed medicine price controls, which aim to ensure affordable medications, may not materialise any time soon, possibly because medicine prices in Malaysia are already competitive as compared to the benchmarked countries. Moreover, based on the comparative pricing analysis of the top five therapeutic areas in selected Asia Pacific countries by the Pharmaceutical Association of Malaysia (PhAMA) in 2015, pricing of medications in Malaysia does not appear excessive (Fig 8), and may not warrant a price-control mechanism. In addition, a price-control mechanism, if it were to materialise, may pose a risk to patient access to the latest and most innovative medications, as multinational single-source medicine producers may be discouraged from introducing products in a market deemed less lucrative.


### Retraction of proposed medicine price controls positive for hospitals

As an alternative, private hospitals, general practitioner clinics and pharmacies may be required to publish their prices to improve market transparency and encourage more competition in the market. With greater transparency, patients will have the option to choose the brand and price of drugs that are within their budget. While the hospital operators may raise other non-regulated charges to cushion the adverse impact from medicine price controls (if materialised), we think that an announcement of a possible call-off of the proposed medicine price controls by the MoH could help to mitigate uncertainties and should be positive for the hospital operators.

Out think. Out perform.

**Fig 8: Ex-manufacturer drug price differential of other countries vs. Malaysia**

Percentage above or below baseline of Malaysia's price in 2014



Note: Includes prescription products from all channels, including private and public sectors  
 Source: Pharmaceutical Association of Malaysia (PhAMA), IMS 2014

**4Q19 results preview**

For the upcoming release of 4Q19 results, we continue to expect the private hospital players, namely IHH and KPJ, to record healthy patient volume growth. However, on the bottom line, we expect IHH to report a lower core net profit due to the start-up expenses from Gleneagles Chengdu (opened doors in October 2019). For pharmaceutical players under our coverage, we expect both Apex and YSP to continue to record margin recoveries, mainly driven by the commercial production of a new plant for the former and the improvement in efficiency of new production lines for the latter.

**Maintain Overweight, with Apex as our top pick**

We maintain our Overweight view on the sector with Apex as our preferred pick. We continue to like the sector for its defensiveness and long-term growth prospects. Going into 2020, we recommend positioning in the pharmaceutical space as a potential earnings recovery play and beneficiary of the government’s initiatives to liberalise the drug distribution in the country. Key downside risks include sharp declines in patient volumes, higher-than-expected start-up losses for new hospitals, execution risk, currency risk, product recall risk and regulatory risk.

## Important Disclosures and Disclaimer

### Equity Rating Structure and Definitions

---

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

---

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable and is not to be taken in substitution for the exercise of your judgment. Such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (expressed or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. You should obtain independent financial, legal, tax or such other professional advice, when making your independent assessment, review and evaluation of the company/entity covered in this report and the risks involved, before investing or participating in any of the securities or investment strategies or transactions discussed in this report. Facts, information, estimates, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel and the same are subject to change without notice. Under no circumstances shall the Company, be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned in this report. The Company, its directors, its employees and their respective associates may also act as market maker, may have assumed an underwriting commitment, deal with such securities and may also perform or seek to perform investment banking services, advisory and other services relating to the subject company/entity mentioned in this report, and may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The Company, its directors, its employees and their respective associates, may provide, or have provided in the past 12 months investment banking, corporate finance or other services and may receive, or may have received compensation for the services provided from the subject company/entity covered in this report. No part of the research analyst's compensation or benefit was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Employees of the Company may serve as a board member of the subject company/entity covered in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have any liability for any damages of any kind relating to such data.

This report, or any portion thereof may not be reprinted, sold or redistributed without the written consent of the Company.

This report is printed and published by:  
Affin Hwang Investment Bank Berhad (14389-U)  
A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,  
69, Jalan Raja Chulan,  
50200 Kuala Lumpur, Malaysia.

T : + 603 2146 7544/7481/7487  
F : + 603 2146 7630  
research@affinhwang.com

[www.affinhwang.com](http://www.affinhwang.com)